Form 4: Bristol-Myers Squibb Executive Reports Changes in Beneficial Ownership
SEC Form 4
Robert M. Plenge, EVP and Chief Research Officer at Bristol-Myers Squibb, reports transactions involving common stock and market share units.
Summary
- Robert M. Plenge, an executive at Bristol-Myers Squibb, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
- The transactions include the vesting and cancellation of market share units and performance shares.
- Some market share units were adjusted or cancelled due to performance factors not meeting minimum payout thresholds.
- Plenge's direct holdings of common stock changed due to these transactions, and he also has indirect holdings through a BMS Savings and Investment Program and a family trust.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing detailing executive compensation. The cancellation of some market share units due to performance is a slightly negative signal, but overall the document is neutral.
Negatives
- Cancellation of market share units due to not meeting minimum performance payout factors indicates underperformance relative to targets.
Risks
- The value of Plenge's holdings is subject to the performance of Bristol-Myers Squibb's stock.
- Future vesting of market share units and performance shares is contingent on meeting performance criteria.
Future Outlook
Future vesting of market share units and performance shares is contingent on meeting performance criteria, with vesting dates extending to 2028.
Industry Context
Executive compensation through stock options and share units is a common practice in the pharmaceutical industry to align management interests with shareholder value.
Comparison to Industry Standards
- Companies like Pfizer (PFE) and Merck (MRK) also utilize stock options and performance-based equity awards as part of their executive compensation packages.
- The specific terms of these awards, such as vesting schedules and performance metrics, can vary significantly between companies.
- The payout factors for Bristol-Myers Squibb's market share units (60%-200% or 80%-225%) are within the typical range for performance-based equity awards in the pharmaceutical industry.
Stakeholder Impact
- Shareholders are impacted by executive compensation decisions, as they can influence company performance and stock value.
- Employees may be impacted by the performance metrics used to determine executive compensation, as these metrics can drive company strategy and priorities.
Key Dates
| Date | Description |
|---|---|
| 03/10/2020 | Grant date of market share units, one-quarter of which vested on 03/10/2024. |
| 03/10/2021 | Grant date of market share units, one-quarter of which vested on 03/10/2024. |
| 03/10/2022 | Grant date of market share units, one-quarter of which was cancelled on 03/10/2024 due to not achieving the 80% minimum payout factor. |
| 03/10/2023 | Grant date of market share units, one-quarter of which was cancelled on 03/10/2024 due to not achieving the 80% minimum payout factor. |
| 03/10/2024 | Date of transactions reported in the Form 4, including vesting and cancellation of market share units and distribution of performance shares. |
| 03/12/2024 | Date of signature of the Form 4 filing. |
| First quarter 2024 | Distribution of performance shares earned under the 2021-2023 Long-Term Performance Award. |
| 03/10/2025 | Future vesting date for market share units granted on March 10, 2021. |
| 03/10/2026 | Future vesting date for market share units granted on March 10, 2022. |
| 03/10/2027 | Future vesting date for market share units granted on March 10, 2023 and distribution of performance shares. |
| 03/10/2028 | Future vesting date for market share units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.